| Title: |
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma |
| Authors: |
Costa, Luciano J.; Bahlis, Nizar J.; Perrot, Aurore; Nooka, Ajay K.; Lu, Jin; Pawlyn, Charlotte; Mina, Roberto; Caeiro, Gaston; Kentos, Alain; Hungria, Vania; Reece, Donna; Niu, Ting; Mylin, Anne K.; Hansen, Charlotte T.; Teipel, Raphael; Besemer, Britta; Dimopoulos, Meletios A.; Zamagni, Elena; Yoshihara, Satoshi; Kim, Kihyun; Min, Chang Ki; Geerts, Paul; Van Leeuwen-Segarceanu, Elena; Tyczynska, Agata; Reguera, Juan Luis; Johansson, Magnus; Hansson, Markus; Turgut, Mehmet; Grey, Mark; Sidana, Surbhi; Rodriguez-Otero, Paula; Martinez-Lopez, Joaquin; Hashmi, Hamza; Carson, Robin; Kobos, Rachel; Sun, Weili; Lantz, Kristen; Seifert, Anne; Briseno-Toomey, Deborah; O'Rourke, Lisa; Rubin, Maria; Vieyra, Diego; Kang, Lijuan; Mateos, Maria Victoria |
| Contributors: |
Costa, Luciano J.; Bahlis, Nizar J.; Perrot, Aurore; Nooka, Ajay K.; Lu, Jin; Pawlyn, Charlotte; Mina, Roberto; Caeiro, Gaston; Kentos, Alain; Hungria, Vania; Reece, Donna; Niu, Ting; Mylin, Anne K.; Hansen, Charlotte T.; Teipel, Raphael; Besemer, Britta; Dimopoulos, Meletios A.; Zamagni, Elena; Yoshihara, Satoshi; Kim, Kihyun; Min, Chang Ki; Geerts, Paul; Van Leeuwen-Segarceanu, Elena; Tyczynska, Agata; Reguera, Juan Lui; Johansson, Magnu; Hansson, Marku; Turgut, Mehmet; Grey, Mark; Sidana, Surbhi; Rodriguez-Otero, Paula; Martinez-Lopez, Joaquin; Hashmi, Hamza; Carson, Robin; Kobos, Rachel; Sun, Weili; Lantz, Kristen; Seifert, Anne; Briseno-Toomey, Deborah; O'Rourke, Lisa; Rubin, Maria; Vieyra, Diego; Kang, Lijuan; Mateos, Maria Victoria |
| Publication Year: |
2026 |
| Collection: |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: |
Teclistamab plus Daratumumab; Relapsed; Refractory; Multiple Myeloma |
| Description: |
Background In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma. Methods In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee. Results A total of 587 patients underwent randomization (291 to receive teclistamab-daratumumab and 296 to receive DPd or DVd). At a median of 34.5 months, progression-free survival was significantly longer with teclistamab-daratumumab than with DPd or DVd. The estimated 36-month progression-free survival was 83.4% in the teclistamab-daratumumab group and 29.7% in the DPd or DVd group (hazard ratio, 0.17; 95% confidence interval, 0.12 to 0.23; P |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41363801; info:eu-repo/semantics/altIdentifier/wos/WOS:001633816000001; volume:394; issue:8; firstpage:739; lastpage:752; numberofpages:14; journal:THE NEW ENGLAND JOURNAL OF MEDICINE; https://hdl.handle.net/11585/1050392 |
| DOI: |
10.1056/nejmoa2514663 |
| Availability: |
https://hdl.handle.net/11585/1050392; https://doi.org/10.1056/nejmoa2514663 |
| Accession Number: |
edsbas.781BD7B6 |
| Database: |
BASE |